Clinical Trial

Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
1. A predictive model for NARDS was established based on perinatal risk factors. Multivariate Logistic regression analysis was used to screen the independent prenatal risk factors for NARDS. A Logistic regression model was constructed using the above independent risk factors and quantified in a nomogram to construct a visualization model for prenatal prediction of NARDS. 2. The role of ACS in the prevention and treatment of ARDS in near-term/full-term infants. For neonates with a probability greater than 80% in the prediction model of ARDS, at least one ACS was given before the termination of pregnancy. The GC level of cord blood (taken at birth) and the mRNA levels of α-ENaC, Na-K-atpase and SGK1 in nasal epithelium were measured within 2 hours and 1 day after birth in the ACS intervention group and the control group. The occurrence and severity of pulmonary edema, the occurrence and severity of ARDS, and the mortality rate of NARDS were evaluated by lung ultrasound. The indexes of the two groups were compared horizontally and longitudinally.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-01; most recent amendment 2025-06-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-02
Trial Details
NCT Number NCT06188195
Lead Sponsor The Second Affiliated Hospital of Chongqing Medical University
Collaborators: University-Town Hospital of Chongqing Medical University, Children's Hospital of Chongqing Medical University, Chongqing Medical Center for Women and Children
Conditions Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome, Acute
Enrollment 500 participants
Start Date 2024-02-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-04